1,531 results on '"Sperr, Wolfgang R"'
Search Results
52. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils
53. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
54. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
55. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives
56. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis
57. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
58. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
59. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
60. Identification of a leukemia-initiating stem cell in human mast cell leukemia
61. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research
62. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
63. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
64. Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma
65. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
66. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
67. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML
68. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications
69. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
70. CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis
71. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
72. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives
73. Time-dependent changes in mortality and transformation risk in MDS
74. Critically ill patients with cancer: chances and limitations of intensive care medicine—a narrative review
75. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
76. Mast cell leukemia:clinical and molecular features and survival outcomes of patients in the ECNM Registry
77. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
78. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
79. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
80. Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
81. Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
82. Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
83. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
84. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
85. Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
86. Influenza vaccination perception and coverage among patients with malignant disease
87. Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features
88. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V(+) systemic mastocytosis: a preclinical study
89. Diagnostic Criteria and Classification of Myelodysplastic Syndromes
90. Supplemental Table S3 from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
91. Supplementary Table 6 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
92. Supplementary Table 7 - 8 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
93. Data from Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
94. Supplementary Methods, Supplementary Tables 1-5, Supplementary Figures 1-11, Supplementary References from Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
95. Supplementary Figure 2 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
96. Data from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
97. Supplementary Table 5 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
98. Supplementary Figure 3 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
99. Supplementary Tables 1 - 4 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
100. Supplementary Figure 1 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.